The company has not filed an annual or quarterly report since its Q3 FY2018 10-Q, filed Nov 8, 2018. Its latest SEC filing is a SC 13G/A from Feb 14, 2020.
10-Q for Q3 FY2018, filed Nov 8, 2018
The sections below describe the company as of the FY2017 annual report.
Develops targeted cancer medicines for patients with genetically defined cancers.
10-K for FY2017, filed Mar 1, 2018
Loxo develops medicines for patients with genetically defined cancers. For larotrectinib and LOXO-195, Bayer handles commercial activities worldwide, while Loxo and Bayer co-promote in the U.S.
10-K for FY2017, filed Mar 1, 2018Loxo Oncology is a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined…View ↗
In November 2017, we and Bayer entered into an exclusive global collaboration agreement for the development and commercialization of…View ↗
We will lead global development activities and regulatory activities in the U.S. Bayer will lead regulatory activities outside the U.S. and…View ↗
8-K, filed Feb 15, 2019
As a result of Purchaser’s acceptance for payment of all Shares that were validly tendered and not properly withdrawn in accordance with…View ↗
8-K, filed Jan 7, 2019
On January 5, 2019, Eli Lilly and Company, an Indiana corporation (“Parent”), Bowfin Acquisition Corporation, a Delaware corporation and a…View ↗
8-K, filed Nov 27, 2018
Stamford, C.T. and Whippany, N.J., November 26, 2018 — The U.S. Food and Drug Administration (FDA) today approved Vitrakvi®…View ↗
Commercial partnership
Loxo moved from retaining worldwide commercial rights and evaluating international partnerships to sharing U.S. promotion of its TRK medicines with Bayer, while Bayer handles worldwide commercial activities.
10-K for FY2014, filed Mar 27, 2015 10-K for FY2017, filed Mar 1, 2018
Broader target pipeline
The earlier report centered on a TRK inhibitor and described additional targeted candidates; the latest report also lists programs aimed at RET, BTK and FGFR.
10-K for FY2014, filed Mar 27, 2015 10-K for FY2017, filed Mar 1, 2018Pre-clinical research indicates that our lead product candidate, LOXO-101, is a potent and selective inhibitor of tropomyosin receptor…View ↗
· LOXO-292, an oral, potent and selective inhibitor of Rearranged during Transfection (“RET”) tyrosine kinase, a signaling protein.…View ↗
· LOXO-305, an oral, potent and selective inhibitor of Bruton’s tyrosine (“BTK”) that retains inhibitory activity against certain mutated…View ↗
With our scientific knowledge, collaborative partnerships and targeted approach, we are developing multiple small molecule therapeutics…View ↗
Competes with Daiichi Sankyo, Plexxikon, Tesaro, Roche, Novartis, Mirati, Ono Pharmaceutical, Chugai Pharmaceutical, Blueprint Medicines, TP Therapeutics, Deciphera, Array, Eisai, Exelixis, AstraZeneca, Ariad, Pfizer, Taiho Oncology, Nerviano Medical Sciences, and Cancer Research UK
10-K for FY2017, filed Mar 1, 2018We face competition with respect to our current product candidates, and will face competition with respect to future product candidates…View ↗
Loading...
